Immune reconstitution and clinical outcomes in B-ALL patients with versus without pre-HSCT Immunotherapy - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Immune Recovery and Clinical Outcomes After HSCT in B-ALL Patients With or Without Prior Immunotherapy

  • By

  • Yu-Yuan Zeng

  • Guan-Hua Hu

  • Ying-Xi Zuo

  • Pan Suo

  • Lu Bai

  • Feng Zhang

  • Hui-Fang Wang

  • Ying-Jun Chang

  • Meng Lv

  • Xiao-Hui Zhang

  • Yu Wang

  • Lan-Ping Xu

  • Xiao-Jun Huang

  • Lin Wang

  • Yi-Fei Cheng

  • October 21, 2026

Share

Original Source(s)

Immune reconstitution and clinical outcomes in B-ALL patients with versus without pre-HSCT Immunotherapy

  • by Yu-Yuan Zeng, Guan-Hua Hu, Ying-Xi Zuo, Pan Suo, Lu Bai, Feng Zhang, Hui-Fang Wang, Ying-Jun Chang, Meng Lv, Xiao-Hui Zhang, Yu Wang, Lan-Ping Xu, Xiao-Jun Huang, Lin Wang, Yi-Fei Cheng

  • October 21, 2026

Related Content

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Error in Supplement 2

  • October 19, 2026

2026 ASCO Breast Cancer Highlights: BWEL

Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.

  • October 15, 2026

  • 1 min